Template:ID-Parasitic meningitis: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
:::* Preferred regimen: ([[Amphotericin B]] 1.5 mg/kg/day IV q12h for 3 days, followed by [[Amphotericin B]] 1 mg/kg/day IV q24h for 11 days) {{and}} ([[Amphotericin B]] 1.5 mg/kg/day intrathecal q24h for 2 days, followed by [[Amphotericin B]] 1 mg/kg/day intrathecal qod for 8 days) {{and}} [[Azithromycin]] 10 mg/kg/day IV/PO q24h for 28 days {{and}} [[Fluconazole]] 10 mg/kg/day IV/PO q24h for 28 days {{and}} [[Rifampin]] 10 mg/kg/day IV/PO q24h for 28 days {{and}} [[Miltefosine]] 50 mg PO bid–tid for 28 days {{and}} [[Dexamethasone]] 0.15 mg/kg IV q6h for 4 days | :::* Preferred regimen: ([[Amphotericin B]] 1.5 mg/kg/day IV q12h for 3 days, followed by [[Amphotericin B]] 1 mg/kg/day IV q24h for 11 days) {{and}} ([[Amphotericin B]] 1.5 mg/kg/day intrathecal q24h for 2 days, followed by [[Amphotericin B]] 1 mg/kg/day intrathecal qod for 8 days) {{and}} [[Azithromycin]] 10 mg/kg/day IV/PO q24h for 28 days {{and}} [[Fluconazole]] 10 mg/kg/day IV/PO q24h for 28 days {{and}} [[Rifampin]] 10 mg/kg/day IV/PO q24h for 28 days {{and}} [[Miltefosine]] 50 mg PO bid–tid for 28 days {{and}} [[Dexamethasone]] 0.15 mg/kg IV q6h for 4 days | ||
::* '''Toxoplasma gondii''' | ::* '''Toxoplasma gondii'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref> | ||
:::* Preferred regimen: [[Sulfadiazine]] 4–6 g/day q6h {{and}} [[Pyrimethamine]] 25–100 mg/day qd | :::* Preferred regimen: [[Sulfadiazine]] 4–6 g/day q6h {{and}} [[Pyrimethamine]] 25–100 mg/day qd | ||
:::* Alternative regimen (1): [[Pyrimethamine]] 25–100 mg/day qd {{and}} [[Clindamycin]] 2400–4800 mg/day IV q6h | :::* Alternative regimen (1): [[Pyrimethamine]] 25–100 mg/day qd {{and}} [[Clindamycin]] 2400–4800 mg/day IV q6h | ||
Revision as of 00:07, 20 June 2015
- Meningitis, parasitic
- Protozoal meningitis
-
- Preferred regimen: (Amphotericin B 1.5 mg/kg/day IV q12h for 3 days, followed by Amphotericin B 1 mg/kg/day IV q24h for 11 days) AND (Amphotericin B 1.5 mg/kg/day intrathecal q24h for 2 days, followed by Amphotericin B 1 mg/kg/day intrathecal qod for 8 days) AND Azithromycin 10 mg/kg/day IV/PO q24h for 28 days AND Fluconazole 10 mg/kg/day IV/PO q24h for 28 days AND Rifampin 10 mg/kg/day IV/PO q24h for 28 days AND Miltefosine 50 mg PO bid–tid for 28 days AND Dexamethasone 0.15 mg/kg IV q6h for 4 days
- Toxoplasma gondii[3]
- Preferred regimen: Sulfadiazine 4–6 g/day q6h AND Pyrimethamine 25–100 mg/day qd
- Alternative regimen (1): Pyrimethamine 25–100 mg/day qd AND Clindamycin 2400–4800 mg/day IV q6h
- Alternative regimen (2): Pyrimethamine 25–100 mg/day qd AND (Azithromycin 1200–1500 mg/day IV q24h OR Atovaquone 750 mg IV q6h OR Dapsone 100 mg PO q24h)
- Alternative regimen (3): TMP-SMZ 10–20 mg/kg/day q6–12h
- Helminthic meningitis
-
- Preferred regimen: Albendazole 15–20 mg/kg/day PO qd–bid for 10–20 days AND Dexamethasone 10–20 mg PO qd for 10–20 days
- Alternative regimen: Mebendazole 100 mg PO bid for 10–20 days AND Dexamethasone 10–20 mg PO qd for 10–20 days
- Baylisascaris procyonis
Preferred Regimen ▸ Albendazole 25–50 mg/kg PO qd or 400 mg PO bid for 10 days PLUS ▸ Dexamethasone 10–20 mg PO qd for 10 days Alternative Regimen ▸ Thiabendazole 50 mg/kg/day PO bid for 10 days PLUS ▸ Dexamethasone 10–20 mg PO qd for 10 days Adapted from Clin Microbiol Rev. 2005;18(4):703-18. and Clin Infect Dis. 2004;15;39(10):1484-92.[14][15]
- Gnathostoma spinigerum
Preferred Regimen ▸ Albendazole 400 mg PO bid for 3 weeks PLUS ▸ Dexamethasone 10–20 mg PO qd for 3 weeks Alternative Regimen ▸ Ivermectin 0.2 mg/kg PO qd for 2 days PLUS ▸ Dexamethasone 10–20 mg PO qd for 3 weeks Adapted from Clin Microbiol Rev. 2009;22(3):484-92. and Clin Infect Dis. 2009;48(3):322-7.[16][13]
- ↑ Linam, W. Matthew; Ahmed, Mubbasheer; Cope, Jennifer R.; Chu, Craig; Visvesvara, Govinda S.; da Silva, Alexandre J.; Qvarnstrom, Yvonne; Green, Jerril (2015-03). "Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis". Pediatrics. 135 (3): –744-748. doi:10.1542/peds.2014-2292. ISSN 1098-4275. PMID 25667249. Check date values in:
|date=(help) - ↑ Vargas-Zepeda, Jesús; Gómez-Alcalá, Alejandro V.; Vásquez-Morales, José Alfonso; Licea-Amaya, Leonardo; De Jonckheere, Johan F.; Lares-Villa, Fernando (2005-02). "Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin". Archives of Medical Research. 36 (1): 83–86. ISSN 0188-4409. PMID 15900627. Check date values in:
|date=(help) - ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
- ↑ Wang, Qiao-Ping; Lai, De-Hua; Zhu, Xing-Quan; Chen, Xiao-Guang; Lun, Zhao-Rong (2008-10). "Human angiostrongyliasis". The Lancet. Infectious Diseases. 8 (10): 621–630. doi:10.1016/S1473-3099(08)70229-9. ISSN 1473-3099. PMID 18922484. Check date values in:
|date=(help) - ↑ Ramirez-Avila, Lynn; Slome, Sally; Schuster, Frederick L.; Gavali, Shilpa; Schantz, Peter M.; Sejvar, James; Glaser, Carol A. (2009-02-01). "Eosinophilic meningitis due to Angiostrongylus and Gnathostoma species". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 48 (3): 322–327. doi:10.1086/595852. ISSN 1537-6591. PMID 19123863.